Global Immuno-Oncology Assay Market is expected to reach USD 18.1 billion by 2034

The global immuno-oncology assay market is estimated to be worth USD 5.6 billion in 2024 and is projected to be valued at USD 18.1 billion in 2034. Between 2024 and 2034, the industry is expected to register a CAGR of 12.4%.

The increasing adoption of immunotherapy in cancer treatment is driving the demand for immuno-oncology assays. These assays are crucial for assessing the efficacy of immunotherapeutic agents, predicting patient responses, and monitoring treatment outcomes.

There is a growing emphasis on biomarker-driven approaches in cancer care, leading to the discovery of novel biomarkers associated with immunotherapy response. Immuno-oncology assays play a critical role in identifying predictive and prognostic biomarkers, and facilitating personalized treatment strategies.

Burgeoning investments in immuno-oncology research and clinical trials is driving market growth. Pharmaceutical companies, biotechnology firms, and academic institutions are conducting extensive research to develop novel immunotherapies and validate immuno-oncology assays in clinical settings.

Favorable regulatory frameworks and reimbursement policies for immuno-oncology assays are facilitating market growth. Regulatory approvals and reimbursement coverage increase the adoption of immuno-oncology assays in clinical practice, driving market expansion.

Key Takeaways from the Market Study

  • From 2019 to 2023, the immuno-oncology assay market expanded at a CAGR of 15.4%.
  • Based on technology, the Checkpoint Inhibitors segment is expected to rise at a CAGR of 11.9% during the forecast period.
  • The immuno-oncology assay demand in South Korea is predicted to flourish at a CAGR of 15.2% through 2034.
  • In the United States, the immuno-oncology assay industry is estimated to register a CAGR of 12.1% from 2024 to 2034.
  • The United Kingdom is projected to expand by a CAGR of 13.9% between 2024 and 2034.
  • The immuno-oncology assay market in Japan is anticipated to record a CAGR of 14.1% during 2034.

The growing acceptance and utilization of immunotherapy across various cancer types drive the demand for immuno-oncology assays, fueling market growth,” says an FMI analyst.

Growing Need for Market Insights: Access Our Full Report for Thorough Analysis and Trends!

Competitive Landscape

Key players in the sector have fortified their global market positions through the adoption of innovative products and substantial research and development endeavors. As competition intensifies, numerous companies are directing their efforts toward research and the introduction of new diagnostic methodologies, expanding their product lines, and pursuing acquisitions and mergers.

  • Bio-Rad Laboratories provides a wide range of life science research tools, including instruments, reagents, and assays for genomics, proteomics, and cell biology. Its offerings support various aspects of immuno-oncology assay development and validation.
  • Hoffmann-La Roche Ltd. is a leading provider of diagnostics and pharmaceuticals, offering companion diagnostics for immuno-oncology therapies, as well as research tools and assays for biomarker discovery and validation.
  • PerkinElmer offers a range of solutions for immuno-oncology research, including imaging systems, high-content screening platforms, and reagents for cellular and molecular analysis.

Key Companies Profiled:

AGILENT TECHNOLOGIES; Sartorius AG; NanoString Technologies; THERMO FISHER SCIENTIFIC; BIO-RAD LABORATORIES; F. HOFFMANN-LA ROCHE LTD.; PERKINELMER; ILLUMINA; QIAGEN N.V.; Charles River Laboratories

Immuno Oncology Assay Market – Key Segments

By Product:

  • Reagents and Antibodies
  • Instruments
  • Software
  • Consumables and Accessories

By Technology:

  • Checkpoint Inhibitors
  • Cytokines & Immunomodulators
  • Monoclonal Antibodies
  • Other Technologies

By indication:

  • Melanoma
  • Colorectal Cancer
  • Lung Cancer
  • Other Cancers

By End-User:

  • Hospitals
  • Clinics
  • Cancer Research Centers

By Application:

  • Research Applications
  • Clinical Diagnostics

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia and Pacific
  • East Asia
  • Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: 
sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

Leave a comment

Your email address will not be published. Required fields are marked *